Mediclinic International (LON:MDC) was upgraded by research analysts at HSBC to a “hold” rating in a research note issued to investors on Thursday. The firm currently has a GBX 390 ($5.10) target price on the stock, down from their prior target price of GBX 540 ($7.06). HSBC’s price objective points to a potential upside of 11.05% from the stock’s previous close.
A number of other research firms have also issued reports on MDC. Barclays reduced their price target on shares of Mediclinic International from GBX 751 ($9.81) to GBX 700 ($9.15) and set an “overweight” rating for the company in a research report on Tuesday, August 7th. Credit Suisse Group reduced their price target on shares of Mediclinic International from GBX 660 ($8.62) to GBX 550 ($7.19) and set a “neutral” rating for the company in a research report on Thursday, August 9th. Finally, Citigroup raised shares of Mediclinic International to a “buy” rating in a research report on Tuesday, October 2nd. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Mediclinic International has an average rating of “Hold” and an average price target of GBX 560.17 ($7.32).
LON MDC opened at GBX 351.20 ($4.59) on Thursday. Mediclinic International has a 52-week low of GBX 495.40 ($6.47) and a 52-week high of GBX 890.18 ($11.63).
Mediclinic International plc, together with its subsidiaries, operates private hospitals. The company offers acute care, specialist-orientated, and multidisciplinary healthcare services under the Mediclinic and Hirslanden brand names. It operates 17 private acute care hospitals and 4 clinics with approximately 1,805 inpatient beds in Switzerland; 49 acute care private hospitals and 2 day clinics in South Africa, and 3 hospitals in Namibia with approximately 8,131 inpatient beds; and 6 acute care private hospitals and 22 clinics with approximately 748 inpatient beds in the United Arab Emirates.
See Also: Diversification in Investing
Receive News & Ratings for Mediclinic International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mediclinic International and related companies with MarketBeat.com's FREE daily email newsletter.